Owlet debuts new Dream Sock at Kind + Jugend
2024 and shares that the device will soon be available to even more
parents across the globe.
Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer
of smart infant monitoring, announced today at Kind + Jugend in
Cologne, Germany, that medically-certified Dream Sock will soon be
available in even more countries, including Poland, Greece, and the
Czech Republic. Dream Sock is the Company’s medically-certified
baby monitor accessible across Europe, giving parents safe and
accurate health readings and actionable alarms while their baby
sleeps.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240903971490/en/
Owlet Dream Sock (Photo: Business
Wire)
“Dream Sock has already made a huge impact on thousands of
families since its global launch a few months ago, and we are eager
to continue the roll-out of our medical-grade technology to even
more parents,” said Kurt Workman, Owlet Chief Executive Officer and
Co-Founder. “We are attending Kind + Jugend this week to meet with
current and potential distribution partners to demonstrate our
latest technology and show the impact Owlet is having across the
world.”
Dream Sock is CE and UKCA Marked under EU and UK Medical Device
Regulations and meets rigorous regulatory standards, ensuring its
safety, efficacy, and compliance with all applicable requirements.
This smart digital health infant monitoring device comfortably
wraps around Baby's foot, providing real-time monitoring of pulse
rate, oxygen saturation level, sleep patterns, and more. The
connected Owlet Dream App (available on iOS and Android) delivers
live health readings directly to mobile devices and the included
Base Station – both of which will immediately notify users if Baby
has low/high pulse rate, or low oxygen. It is clinically proven to
accurately track and display an infant’s vital signs and is
intended for healthy infants between 0-18 months and 2.5-13.6 kg.
Dream Sock can also be paired with the Owlet Cam® 2 allowing
caregivers to see and hear Baby from anywhere, receive motion
notifications, and more.
Dream Sock is available now for purchase in the UK and select
European markets. Dream Sock will be available in the following
markets via Owlet’s localized websites and key retailers in the
coming weeks: Poland, the Czech Republic, Slovakia, Hungary,
Romania, Bulgaria, and Greece.
About Owlet, Inc. Owlet’s digital health infant
monitoring platform is transforming the journey of parenting. The
Company (NYSE:OWLT), a small-cap healthcare growth equity, offers
FDA-authorized medical and consumer pediatric wearables and an
integrated HD visual and audio camera that provide real-time data
and insights to parents who safeguard health, optimize wellness,
and ensure peaceful sleep for their children.
Since 2012, over 2 million parents worldwide have used Owlet’s
platform contributing to one of the largest collections of consumer
infant health and sleep data. The Company continues to develop
software and digital data solutions to bridge the current
healthcare gap between hospital and home and bring new insights to
parents and caregivers globally. Owlet believes that every child
deserves to live a long, happy, and healthy life. To learn more,
visit www.owletcare.com.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 (the “Reform Act”). All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including, without limitation, statements regarding the
Company’s certification and launch of its Dream Sock in the
European Market and the impacts, growth prospects, and expanded
product offerings and product availability in international
markets. In some cases, you can identify forward-looking statements
by terms such as “estimate,” “may,” “believes,” “plans,” “expects,”
“anticipates,” “intends,” “goal,” “potential,” “upcoming,”
“outlook,” “guidance,” the negation thereof, or similar
expressions, although not all forward-looking statements contain
these identifying words. Forward-looking statements are based on
the Company’s expectations at the time such statements are made,
speak only as of the dates they are made and are susceptible to a
number of risks, uncertainties and other factors. For all such
forward-looking statements, the Company claims the protection of
the safe harbor for forward-looking statements contained in the
Reform Act. The Company’s actual results, performance or
achievements may differ materially from any future results,
performance or achievements expressed or implied by our
forward-looking statements. Many important factors could affect the
Company’s future results and cause those results to differ
materially from those expressed in or implied by the Company’s
forward-looking statements. Such factors include, but are not
limited to, (i) the availability of, adoption and commercial
success of Dream Sock and its new medical technology within
additional international markets, (ii) the regulatory pathway for
the Company’s products, including submissions to, actions taken by
and decisions and responses from regulators, such as the FDA and
similar regulators outside of the United States, as well as the
Company’s ability to obtain and maintain regulatory approval or
certification for our products and other regulatory requirements
and legal proceedings; (iii) any developments in litigation in
which the Company is involved, including the Butala and Cherian
cases described in the Company’s reports filed with the U.S.
Securities and Exchange Commission (the “SEC”); (iv) the ability of
the Company to maintain listing of its Class A common stock on a
national stock exchange, including by coming back into compliance
with Section 802.01B of the NYSE Listed Company Manual within the
allotted cure period described in the Company’s reports filed with
the SEC; (v) the Company’s competition and the Company’s ability to
profitably grow and manage growth; (vi) the Company’s ability to
enhance future operating and financial results or obtain additional
financing to continue as a going concern; (vii) risks associated
with the Company’s current loan and debt agreements, including
compliance with debt covenants, restrictions on the Company’s
access to capital, the impact of the Company’s overall debt levels
and the Company’s ability to generate sufficient future cash flows
to meet the Company’s debt service obligations and operate its
business; (viii) the ability of the Company to implement strategic
initiatives, reduce costs, grow revenues, develop and launch new
products, innovate and enhance existing products, meet customer
demands and adapt to changes in consumer preferences and retail
trends; (ix) the Company’s ability to acquire, defend and protect
its intellectual property and satisfy regulatory requirements,
including but not limited to requirements concerning privacy and
data protection, breaches and loss, as well as other risks
associated with the Company’s digital platforms and technologies;
(x) the Company’s ability to maintain relationships with customers,
manufacturers and suppliers and retain Owlet’s management and key
employees; (xi) the Company’s ability to upgrade and maintain its
information technology systems; (xii) changes in applicable laws or
regulations; (xiii) the impact of and disruption to the Company’s
business, financial condition, operations, supply chain and
logistics due to economic and other conditions beyond the Company’s
control, such as health epidemics or pandemics, macro-economic
uncertainties, social unrest, hostilities, natural disasters or
other catastrophic events; (xiv) the possibility that the Company
may be adversely affected by other economic, business, regulatory,
competitive or other factors, such as changes in discretionary
consumer spending and consumer preferences; and (xv) other risks
and uncertainties set forth in the Company’s other releases, public
statements and filings with the SEC, including those identified in
the “Risk Factors” section of the Company’s Annual Report on Form
10-K for the fiscal year ended December 31, 2023, subsequent
Quarterly Reports on Form 10-Q, and any current or periodic reports
filed with the SEC. All such forward-looking statements
attributable to the Company or any person acting on the Company’s
behalf are expressly qualified in their entirety by the cautionary
statements contained or referred to above. Moreover, the Company
operates in an evolving environment. New risk factors and
uncertainties may emerge from time to time, and factors that the
Company currently deems immaterial may become material, and the
Company can't predict such events or how they may affect the
Company. Except as required by law, the Company assumes no
obligation to update any forward-looking statements after the date
of this press release, whether because of new information, future
events or otherwise, although the Company may do so from time to
time. The Company does not endorse any projections regarding future
performance that may be made by third parties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903971490/en/
Media: pr@owletcare.com
Sandbridge Aquisition (NYSE:OWLT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sandbridge Aquisition (NYSE:OWLT)
Historical Stock Chart
From Dec 2023 to Dec 2024
